Skip to main content

Advertisement

SpringerLink
Log in

Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics

  • Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Youth receiving treatment with antipsychotics are particularly susceptible to weight gain, type 2 diabetes (T2D), and associated metabolic disorders, which is directly associated with excess morbidity and mortality in this vulnerable population. The risk of T2D is 2- to 3-fold that of the general population, starts early in the course of treatment, and reflects the effects of weight gain in conjunction with direct effects of antipsychotics on the hypothalamus, pancreatic beta cells, and insulin-sensitive peripheral tissues. Close monitoring with early intervention through lifestyle intervention, switching away from antipsychotics with deleterious metabolic effects, and adjunctive treatment with metformin are modalities available to mitigate weight gain and improve cardiometabolic health in these patients. Despite rapidly advancing knowledge in the field, patient’s access to metabolic screening and quality care remains limited. Efforts must be made to broaden reach of early cardiometabolic intervention among these patients in order to avert serious cardiovascular disease burden in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry: J Mental Sci. 2010;196(2):116–21.

    Article  Google Scholar 

  2. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64–6.

    Article  PubMed  Google Scholar 

  3. Casagrande SS, Anderson CA, Dalcin A, Appel LJ, Jerome GJ, Dickerson FB, et al. Dietary intake of adults with serious mental illness. Psychiatric Rehabil J. 2011;35(2):137–40.

    Article  Google Scholar 

  4. Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009;31(6):555–63.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014;311(2):172–82.

    Article  PubMed  Google Scholar 

  6. Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861–7.

    Article  PubMed  Google Scholar 

  7. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123(2–3):234–43.

    Article  CAS  PubMed  Google Scholar 

  8. Kilbourne AM, McCarthy JF, Post EP, Welsh D, Pincus HA, Bauer MS, et al. Access to and satisfaction with care comparing patients with and without serious mental illness. Int J Psychiatry Med. 2006;36(4):383–99.

    Article  PubMed  Google Scholar 

  9. Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol. 2010;24(4 Suppl):61–8.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–56.

    Article  PubMed  Google Scholar 

  11. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacol. 2008;23 Suppl 1:15–26.

    Article  Google Scholar 

  12. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460–6.

    Article  CAS  PubMed  Google Scholar 

  13. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067–75. Recent estimates of T2D disease burden in youths taking antipsychotics in the US.

    Article  PubMed  Google Scholar 

  14. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135–41.

    Article  PubMed  Google Scholar 

  15. Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case–control study. J Am Acad Child Adolesc Psychiatry. 2014;53(9):971–9 e6. Recent estimates of T2D disease burden in youths taking antipsychotics in Denmark.

    Article  PubMed  Google Scholar 

  16. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008;42(9):1316–22.

    Article  PubMed  Google Scholar 

  17. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63. Describes metabolic profile of a young patient cohort early on in the course of psychiatric disease.

    Article  PubMed  Google Scholar 

  18. Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15(3):202–14.

    Article  CAS  PubMed  Google Scholar 

  19. Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18(8):1646–51.

    Article  CAS  Google Scholar 

  20. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends endocrinol Metabolism: TEM. 2014;25(11):593–600. Excellent review of hypothesis and recent findings on antipsychotics and diabetes.

    Article  CAS  Google Scholar 

  21. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity Metabolism. 2009;11(7):665–79.

    Article  PubMed  Google Scholar 

  22. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341–50.

    Article  PubMed  Google Scholar 

  23. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–26. Comprehensive review on the topic.

    Article  Google Scholar 

  24. Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79–89. Comprehensive review on the topic.

    Article  PubMed  Google Scholar 

  25. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry: J Assoc Eur Psychiatrists. 2011;26(3):144–58.

    Article  Google Scholar 

  26. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4), e94112. Summarizes data on weight gain associated with various antipsychotics.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–33.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–59.

    Article  PubMed  Google Scholar 

  30. Kao AC, Muller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics. 2013;14(16):2067–83. Comprehensive review on the topic.

    Article  CAS  PubMed  Google Scholar 

  31. Shams TA, Muller DJ. Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Current Psychiatry Reports. 2014;16(10):473. Comprehensive review on the topic.

    Article  PubMed  Google Scholar 

  32. Ngai YF, Sabatini P, Nguyen D, Davidson J, Chanoine JP, Devlin AM, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014;34(3):359–64. Demonstrates effects of quetiapine on beta cell function in youths.

    Article  CAS  PubMed  Google Scholar 

  33. Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Shiffeldrim D, et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013;143(2–3):358–62.

    Article  PubMed  Google Scholar 

  34. Starrenburg FC, Bogers JP. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(3):164–70.

    Article  CAS  Google Scholar 

  35. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232–40. Demonstrates weight-independent effects of antipsychotics on insulin resistance.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.

  37. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(6):412–24.

    Article  Google Scholar 

  38. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry: J Mental Sci. 2011;199(2):99–105.

    Article  Google Scholar 

  39. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, Cg g. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Canadian Acad Child Adolescent Psychiatry. 2011;20(3):218–33.

  40. Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73(4):460–6. Describes prevalence and clinical characteristics of prediabetes in this patient group.

    Article  CAS  PubMed  Google Scholar 

  41. American Diabetes Association. Standards of Medical Care in Diabetes. 11. Children and adolescents. Diabetes Care. 2015;38(Supplement 1):S70–S6.

    Article  Google Scholar 

  42. Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82.

    Article  PubMed  Google Scholar 

  43. National Institute for Health and Clinical Excellence. Diabetes in children and young people: diagnosis and management of type 1 and type 2 diabetes in children and young people. London, UK. 2015. http://www.nice.org.uk/guidance/indevelopment/gid-cgwaver118.

  44. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

    Article  CAS  PubMed  Google Scholar 

  45. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.

    Article  CAS  PubMed  Google Scholar 

  46. Werneke U, Taylor D, Sanders TA. Behavioral interventions for antipsychotic induced appetite changes. Current Psychiatry Reports. 2013;15(3):347. Discusses aspects of behavioral intervention in this patient group.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):e424–40.

    Article  PubMed  Google Scholar 

  48. Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71–81. Evaluates efficacy of lifestyle intervention in patients with SMI who receive antipsychotics.

    Article  PubMed  Google Scholar 

  49. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–602. Evaluates efficacy of lifestyle intervention in patients with SMI, most of whom receive antipsychotics.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Arnoldy R, Curtis J, Samaras K. The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabet Med. 2014;31(3):e16–9. A case report demonstrating dramatic effects of antipsychotic switching on glucose metabolism.

    Article  CAS  PubMed  Google Scholar 

  51. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12, CD006629.

    PubMed  Google Scholar 

  52. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry: J Assoc Eur Psychiatrists. 2010;25 Suppl 2:S12–21.

    Article  Google Scholar 

  53. Curtis J, Newall H, Myles N, Shiers D, Samaras K. Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatr Scand. 2012;126(4):302–3. Perspectives on the topic.

    Article  CAS  PubMed  Google Scholar 

  54. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol. 2012;27(2):69–75. Review of metformin use in adults and pediatric patients with psychiatric illnesses.

    Article  PubMed  Google Scholar 

  55. Hasnain M, Fredrickson SK, Vieweg WV. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J Psychopharmacol. 2011;25(6):715–21.

    Article  CAS  PubMed  Google Scholar 

  56. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–403. Review of use of metformin and other pharmacological agents in adults and pediatric patients with schizophrenia.

    Article  PubMed  Google Scholar 

  57. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159(4):655–7.

    Article  PubMed  Google Scholar 

  58. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–9.

    Article  PubMed  Google Scholar 

  59. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130–4.

    PubMed  Google Scholar 

  60. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–93.

    Article  CAS  PubMed  Google Scholar 

  61. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925–7.

    Article  CAS  PubMed  Google Scholar 

  62. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry: J Mental Sci. 2009;194(6):491–9.

    Article  Google Scholar 

  63. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–47. Demonstrates disparities in health care among patients with SMI.

    Article  CAS  PubMed  Google Scholar 

  64. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631–8.

    Article  PubMed  Google Scholar 

  65. Shiers D, Curtis J. Cardiometabolic health in young people with psychosis. Lancet Psychiatry. 2014;1(7):492–4. Describes the history and goals of the HeAL initiative.

    Article  Google Scholar 

  66. International physical health in youth stream (iphYs). Healthy Active Lives (HeAL) statement., Sydney, Australia. 2014. http://www.iphys.org.au/. Further information on the HeAL initiative.

  67. Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry. 2012;6(3):347–53. Discusses framework for early cardiometabolic intervention in youths with SMI who receive antipsychotics.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Pornpoj Pramyothin and Lalita Khaodhiar declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Nutrition, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    Pornpoj Pramyothin

  2. Center for Nutrition and Weight Management, Boston Medical Center, School of Medicine, Boston University, 88 East Newton Street Robinson Bldg, Suite 4400, Boston, MA, 02118, USA

    Lalita Khaodhiar

Authors
  1. Pornpoj Pramyothin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lalita Khaodhiar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lalita Khaodhiar.

Additional information

This article is part of the Topical Collection on Pediatric Type 2 Diabetes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pramyothin, P., Khaodhiar, L. Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics. Curr Diab Rep 15, 53 (2015). https://doi.org/10.1007/s11892-015-0623-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-015-0623-4

Keywords

Search

Navigation